P/E ratio for Takeda Pharmaceutical (TAK)

P/E ratio history for Takeda Pharmaceutical from 2009 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	10.7	-62.76%	🇺🇸 USA
Sanofi SNY	16.5	-42.62%	🇫🇷 France
Pfizer PFE	14.3	-50.35%	🇺🇸 USA
Novartis NVS	27.5	-4.69%	🇨🇭 Switzerland
Seagen SGEN	-57.0	-297.81%	🇺🇸 USA
Dr. Reddy's RDY	3.65	-87.34%	🇮🇳 India
Amgen AMGN	19.8	-31.26%	🇺🇸 USA
GlaxoSmithKline GSK	10.0	-65.27%	🇬🇧 UK
Merck MRK	53.5	85.70%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.